InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress

[ad_1]

Female doctor checking on Covid-19 infected patient while connected to a ventilator

Juanmonino/E+ via Getty Images

InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress.

The European Commission granted marketing authorization under exceptional circumstances for Gohibic, also known as vilobelimab, for the treatment of adult patients

[ad_2]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *